[The role of statins in atherosclerotic peripheral arterial disease]

Rev Port Cardiol. 2011 Jul;30(7-8):665-73. doi: 10.1016/S0870-2551(11)70005-1.
[Article in Portuguese]

Abstract

The use of statins for secondary prevention in patients with peripheral (extracoronary) arterial disease is not widespread. Their possible use has only relatively recently been studied and data in the literature are sometimes controversial or are not disclosed. The aim of this paper is to review the recent literature and to discuss possible reasons for using statins in patients with extracoronary atherosclerotic arterial involvement, focusing on the areas in which they have been investigated. The main conclusions are that statins should be prescribed with the objective of reducing coronary and cerebrovascular morbidity and mortality in patients with carotid disease, abdominal aortic aneurysm and lower limb occlusive disease. There is sufficient evidence to suggest a reduction in the perioperative risk of vascular surgery when statins are used, and in patients with carotid stenosis they also appear to reduce perioperative risk in endarterectomy. Nevertheless, there are insufficient data to recommend the use of statins to control post-endarterectomy restenosis. In patients with intermittent claudication, statins improve walking distance and may be used for this purpose. Finally, there is insufficient evidence to recommend statins to prevent restenosis in lower limb revascularization procedures, to control progression of abdominal aortic aneurysms, or to reduce the severity of renal artery stenosis or renal dysfunction.

Publication types

  • English Abstract
  • Review

MeSH terms

  • Cerebrovascular Disorders / etiology*
  • Cerebrovascular Disorders / prevention & control*
  • Coronary Artery Disease / etiology*
  • Coronary Artery Disease / prevention & control*
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
  • Peripheral Arterial Disease / complications*
  • Peripheral Arterial Disease / drug therapy*
  • Secondary Prevention

Substances

  • Hydroxymethylglutaryl-CoA Reductase Inhibitors